Primary aldosteronism – how many are we missing?

21st November, A/Prof Chee L Khoo

Adrenal tumour

Most of our patients with hypertension have primary (or essential) hypertension. Secondary hypertension is said to be relatively rare. Most causes of secondary hypertension are phaeochromocytoma, renal disease, renal artery stenosis, obstructive sleep apnoea, Cushing’s disease or primary aldosteronism (PA). Most of these diseases are relatively straightforward to diagnose but excluding PA is a little more tricky (see below) and we tend not to chase after that.…

Oral semaglutide finally here – what you need to know

12th November 2026, A/Prof Chee L Khoo

oral semaglutide

We are finally here. Oral semaglutide (or “oral wegovy”) is now TGA approved. As we highlighted oral semaglutide (oralSema) a little over 12 months ago here, oralSema have demonstrated glycaemia and body weight reduction efficacy way back in 2019 in the PIONEER trial. It has also demonstrated cardiovascular benefits. It was approved back in 2019 by the US FDA on the back of the PIONEER trial.…

Coronary FAI – a better way to assess CV risk?

25th October 2026, A/Prof Chee L Khoo

acute coronary syndrome

We all know that hypertension, hyperglycaemia, obesity and elevate LDL-C are risk factors for coronary artery disease. We have also seen that elevated lipoprotein (a) and elevated triglycerides are independent risk factors. We are aware that patients with systemic inflammation (e.g. psoriasis, systemic lupus erythematosus, inflammatory bowel disease, obesity, type 2 diabetes, and non-obstructive coronary syndromes) are also at higher CV risk.…

Is ADHD on the increase?

23rd October 2026, A/Prof Chee L Khoo

Attention-deficit/hyperactivity disorder (ADHD) is not really a disorder. It is a neurodevelopmental condition that affects attention, activity levels, impulse control, organisation, and emotional regulation. Symptoms begin in childhood, but they can continue into adolescence and adulthood. ADHD can affect learning, work, relationships, home life, and self-esteem, but with accurate diagnosis and the right supports, people with ADHD can manage symptoms and thrive.…

The many TRIUMPHs of retatrutide

10th October 2026, A/Prof Chee L Khoo

tri-hormone agonist

The topline results of TRANSCEND-T2D 1 were released in March 2026 and the full results have since been published. It was a trial involving patients with sub-optimally controlled T2D and obesity with the primary aim of better glycaemic control. The TRIUMPH series were designed to primarily demonstrate the efficacy of retatrutide in weight management in patients with obesity +/- T2D and a variety of clinical conditions (see Table 1).…

Digitalis for heart failure – how was it disowned?

20th September 2026, A/Prof Chee L Khoo (in collaboration with A/Prof Masis Perk)

heart failure

It has been12 months now since we highlighted on GPVoice that digitalis is making a comeback in the management of heart failure. We pointed out the important role it has in heart failure (HF) but its use was downplayed in most of the major guidelines. This is despite increasing clinical trial data supporting this old, but well tested drug.…

Silent ischaemia – why are we still missing them?

19th September 2026, A/Prof Chee L Khoo

First event

We know that atherosclerosis is likely to be present for years or decades before clinical disease becomes manifest. Current primary prevention of cardiovascular events is guided largely by calculated risk-factor scores or symptoms of ischaemia. However, these scores are strongly influenced by age and tend to assign low risk to young adults, even in the presence of relevant risk-factor exposure.…

Diabetic Sarcopenia Care in Older Adults with Diabetes – a short survey

5th September, A/Prof Chee L Khoo and A/Prof Shannon Lin

sarcopenia

Diabetes-related sarcopenia, characterised by the loss of muscle mass, strength, and function in people with diabetes, is an emerging but under-recognised complication associated with falls, frailty, hospitalisations, and reduced quality of life. I am working closely with researchers at the University of Technology Sydney (UTS) and we are conducting a short survey to understand health professionals’ awareness, knowledge, and current practices relating to diabetes-related sarcopenia.…

Menopausal hormone therapy – good or bad for CVD?

29th August 2026, A/Prof Chee L Khoo

Menopause

The European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on hormone replacement therapy (HRT)/ menopausal hormone therapy (MHT) (1). It recognised that these women can be appropriately managed in primary care according to recognised guidelines.…

Negative ZEUS trial – does that mean inflammation is not important in CVD?

28th August 2026, A/Prof Chee L Khoo

Atherosclerosis

Atherosclerotic cardiovascular disease (ASCVD) is considered an inflammatory condition. Not only is inflammation central to the initiation of ASCVD, it is also responsible for the progression as well as the destabilisation of atherosclerotic plaque leading to ischaemia. This is in addition to the other well known risk factors (e.g. dyslipidaemia, smoking, hypertension etc) for ASCVD.…

pTau181 biomarker now TGA approved – what does that mean?

13th August 2026, A/Prof Chee L Khoo

is there beta-amyloid in there?

We know (maybe better phrased – we think we know) that it is the amyloid-β (Aβ) plaques that are a key driver of pathological processes in Alzheimer’s disease (AD) (1,2).  Targeting the Aβ should then prevent or at the very least delay the progression of the dementia. The problem with prevention is that we don’t know who are going to get dementia till there is some cognitive impairment.…

Low carbohydrate diet in MAFLD – how important is it?

25th July 2026, A/Prof Chee L Khoo

MAFLD

We know that 55-65% patients with type 2 diabetes (T2D) have metabolic dysfunction associated fatty liver disease (MAFLD) (1). We also know that 28% of patients with MAFLD will develop T2D if not already present by the time MAFLD is detected (2). There is emerging evidence that there are profound alterations in oral glucose handling in individuals with MAFLD even before T2D is diagnosed.…